Biopharmaceuticals
Oncology
FDA
News Release - July 2, 2013
FDA Grants Genentech’s Perjeta Regimen Priority Review for Use Before Surgery in HER2-Positive Early Stage Breast Cancer
Source: Genentech
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.